Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #119379 on NorthWest Biotherapeutics Inc (NWBO)
flipper44
05/28/17 3:38 PM
#119380 RE: iclight #119379
Industry-Expert-Theater in the Oncology-Professionals-Hall at the 2017-ASCO-Annual-Meeting....
INDUSTRY EXPERT THEATER The Industry Expert Theater brings together industry leaders and attendees interested in the latest drug development research. These hour-long educational (non-accredited) presentations take place in the Oncology Professionals Hall on Saturday, Sunday, and Monday. Saturday, June 3 Biosimilar Monoclonal Antibodies: What Oncologists Need to Know 9:30 AM–10:30 AM Amgen Presenter: Richard Markus, VP Biosimilars Global Development, Amgen TECENTRIQ® in Locally Advanced or Metastatic Urothelial Carcinoma (mUC) and Previously Treated Metastatic Non-small Cell Lung Cancer (NSCLC) 12:15 PM–1:15 PM†^ Genentech USA, Inc. Presenter: Fairooz Kabbinavar, MD, FACP Principal Medical Director Product Development Oncology, Genentech, Inc. Current Updates in ALK NSCLC and Brigatinib 3:00 PM–4:00 PM†‡ Takeda Oncology Presenter: David Kerstein, Senior Director, Clinical Development, Takeda Oncology Sunday, June 4 ZEJULA (Niraparib): A Once-Daily Oral Maintenance Treatment For Recurrent Ovarian Cancer Following Response To Platinum-Based Chemotherapy 9:45 AM–10:45 AM‡ TESARO Presenter: Martin Huber, MD, Senior Vice President, Chief Medical Officer, TESARO Insights in Immuno-Oncology: How Antigens and the Tumor Microenvironment Can Shape the Antitumor Immune Response 11:30 AM–12:30 PM Amgen Presenter: Jackson Egen, PhD, Principal Scientist, Department of Oncology Research, Amgen, Inc. From Evidence to Practice: Biosimilar Trastuzumab and Rituximab Biosimilar Trastuzumab and Rituximab are not approved in U.S. yet 4:15 PM–5:15 PM Celltrion Healthcare Presenters: Ho Ung Kim, Head of Strategy and Operations Division, Celltrion Healthcare Hyuk Chan Kwon, MD, Ph.D., Head of Medical Affairs Department, Celltrion Healthcare Byoung Seo Choi, Head of Marketing Department, Celltrion Healthcare Monday, June 5 Extending Overall Survival in Patients with Relapsed or Refractory Multiple Myeloma: Head-to-Head Study Results 9:30 AM - 10:30 AM† Amgen Presenters: Amy Kimball MD PhD, Clinical Research Medical Director, Amgen Andrea Sersch, Executive Medical Director Global Development, Amgen Recent accelerated approval of Bavencio, a checkpoint inhibitor 11:30 AM–12:30 PM† EMD Serono - Pfizer Alliance Presenters: Kevin Chin, Vice President –Clinical Development, EMD Serono Kanwarjit Singh, MD, Team Leader, Oncology Medical Affairs, Pfizer DCVax® - Novel Personalized Immune Therapies for Solid Tumors 3:00 PM - 4:00 PM Northwest Biotherapeutics Presenter: Marnix Bosch, MD, Chief Technical Officer, Northwest Biotherapeutics †Only individuals with an attendee designation on their badge will be admitted. ‡Presentation intended for a U.S. audience only. ^This presentation is intended for US-based HCPs